Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.05 USD
+0.07 (3.54%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Corvus Pharmaceuticals (CRVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.88 | $12.00 | $3.50 | 297.98% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Corvus Pharmaceuticals comes to $7.88. The forecasts range from a low of $3.50 to a high of $12.00. The average price target represents an increase of 297.98% from the last closing price of $1.98.
Analyst Price Targets (4 )
Broker Rating
Corvus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/27/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
3/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 5 |
Average Target Price | $7.88 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.12 |